Ricardo Harold Flores Arotinco

Ricardo Harold Flores Arotinco

Auto-generated profile, based on publicly available information

Ricardo Harold Flores Arotinco


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2025 in IECCMEXICO
Verified
Journal Article
Closed access
FCFabio Camilo Jaramillo Contreras
Fabio Camilo Jaramillo Contreras
NLNelson David Peña Lopez
Nelson David Peña Lopez
AAAna Milena Murgas Acevedo
Ana Milena Murgas Acevedo
MRMarlies Solís Rodríguez
Marlies Solís Rodríguez
JMJosé David Plazas Mora
José David Plazas Mora
ANAlexa Fernanda Uriostegui Navarro
Alexa Fernanda Uriostegui Navarro
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as one of the most significant advances in contemporary oncology, representing a transformative approach within the field of personalized cancer immunotherapy. By genetically engineering T lymphocytes to recognize and eliminate malignant cells through specific antigen-targeting mechanisms, CAR-T therapy has demonstrated remarkable clinical efficacy in several hematological malignancies, including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. This review analyzes the biological foundations, clinical applications, therapeutic outcomes, safety considerations, and future perspectives associated with CAR-T technology. The available evidence indicates that CAR-T therapy has achieved unprecedented response rates in patients with relapsed or refractory disease, significantly improving treatment possibilities for populations with historically poor prognoses. However, important challenges remain regarding treatment-related toxicities, manufacturing complexity, economic sustainability, accessibility, and limited effectiveness in solid tumors. Recent advances in genetic engineering, synthetic biology, biomarker discovery, and precision medicine are driving the development of next-generation CAR-T platforms designed to enhance efficacy, safety, and applicability across a broader spectrum of cancers. Furthermore, growing interest in Latin America, particularly in Mexico, Colombia, and Ecuador, reflects increasing efforts to expand access to advanced cellular therapies through academic collaboration, translational research, and healthcare innovation. The findings suggest that CAR-T therapy will continue to play a central role in the evolution of precision oncology and may serve as a model for future individualized therapeutic strategies in cancer management.

27 December 2025 in IECCMEXICO
Verified
Journal Article
Closed access
MMMario René López Monzón
Mario René López Monzón
RARicardo Harold Flores Arotinco
Ricardo Harold Flores Arotinco
NANathalia Alejandra Montaño Argote
Nathalia Alejandra Montaño Argote
AOAlejandra Mendoza Ortiz
Alejandra Mendoza Ortiz
JTJuan Camilo Manosalva Trillos
Juan Camilo Manosalva Trillos
JMJacqueline Dorian López Molina
Jacqueline Dorian López Molina
Bone fragility has traditionally been associated with osteoporosis and reduced bone mineral density; however, contemporary evidence indicates that fracture risk is influenced by a broader spectrum of metabolic, nutritional, endocrine, inflammatory, and musculoskeletal factors. The objective of this review was to analyze the metabolic determinants associated with bone fragility beyond osteoporosis and to examine their influence on fracture risk and recovery outcomes. A structured narrative review of scientific literature published in major biomedical databases was conducted, focusing on diabetes mellitus, chronic kidney disease, vitamin D deficiency, malnutrition, osteosarcopenia, endocrine dysfunction, and chronic inflammation. The findings demonstrated that these conditions contribute significantly to alterations in bone quality, remodeling capacity, muscle performance, and tissue repair, thereby increasing susceptibility to fragility fractures independently of bone mineral density measurements. Diabetes mellitus and chronic kidney disease emerged as major determinants of skeletal fragility due to their effects on collagen integrity, mineral metabolism, vascular function, and bone turnover. Nutritional deficiencies and inadequate vitamin D status were consistently associated with impaired mineralization, increased fall risk, and delayed fracture healing. Furthermore, osteosarcopenia highlighted the close biological relationship between bone and muscle health and its contribution to fracture susceptibility and functional decline. The evidence supports a multidimensional understanding of skeletal fragility that incorporates metabolic health into fracture prevention and management strategies. Expanding fracture risk assessment beyond traditional osteoporosis models may improve early identification of vulnerable individuals and facilitate more comprehensive approaches to prevention, treatment, and rehabilitation.

28 December 2025 in International Science Journal
Verified
Journal Article
Closed access
FCFabio Camilo Jaramillo Contreras
Fabio Camilo Jaramillo Contreras
MRMarlies Solís Rodríguez
Marlies Solís Rodríguez
MRMichelle Miranda Espejel Romero
Michelle Miranda Espejel Romero
JPJosé Alberto Pérez Pérez
José Alberto Pérez Pérez
JPJosé Antonio Reyes Pinto
José Antonio Reyes Pinto
ANAlexa Fernanda Uriostegui Navarro
Alexa Fernanda Uriostegui Navarro
Cancer remains one of the leading causes of mortality worldwide despite significant advances in diagnosis and treatment. The emergence of personalized messenger RNA (mRNA)-based cancer vaccines has introduced a novel therapeutic strategy capable of integrating genomic medicine, immunology, and biotechnology into precision oncology. The objective of this review was to analyze the current scientific evidence regarding the biological foundations, immunological mechanisms, clinical applications, advantages, limitations, and future perspectives of personalized mRNA cancer vaccines. A scientific method-based narrative review methodology was employed through a structured search of peer-reviewed literature indexed in PubMed, Scopus, Web of Science, ScienceDirect, SpringerLink, and other internationally recognized databases. The evidence demonstrated that personalized mRNA vaccines can encode patient-specific neoantigens, stimulate robust CD4+ and CD8+ T-cell responses, enhance dendritic-cell-mediated antigen presentation, and promote durable immunological memory. Clinical investigations have reported encouraging results in melanoma, pancreatic cancer, glioblastoma, lung cancer, and other malignancies, particularly when vaccines are combined with immune checkpoint inhibitors. The findings also revealed important advantages, including high therapeutic specificity, individualized treatment design, and rapid development capacity. However, challenges related to neoantigen selection, manufacturing costs, regulatory complexity, and healthcare infrastructure remain significant barriers to widespread implementation. From a regional perspective, countries such as Mexico, Colombia, and Ecuador are progressively expanding precision oncology capabilities, although important limitations persist regarding access to genomic technologies and advanced immunotherapies. Overall, personalized mRNA cancer vaccines represent a promising innovation with the potential to transform future cancer treatment through highly individualized and immune-based therapeutic approaches.